Compare SAM & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAM | HTFL |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1996 | 2025 |
| Metric | SAM | HTFL |
|---|---|---|
| Price | $175.81 | $51.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $233.70 | $38.20 |
| AVG Volume (30 Days) | 147.7K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.45 | 82.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,964,994,000.00 | $176,034,000.00 |
| Revenue This Year | $1.02 | $27.66 |
| Revenue Next Year | $1.31 | $23.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.92 |
| 52 Week Low | $158.68 | $20.13 |
| 52 Week High | $264.46 | $51.19 |
| Indicator | SAM | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 80.94 |
| Support Level | $167.97 | $22.96 |
| Resistance Level | $189.24 | $51.19 |
| Average True Range (ATR) | 5.27 | 2.69 |
| MACD | -1.49 | 0.36 |
| Stochastic Oscillator | 7.54 | 95.28 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.